Patents Assigned to NPS Allelix Corporation
  • Publication number: 20040152740
    Abstract: The present invention relates to compounds of Formula 1: 1
    Type: Application
    Filed: September 8, 2003
    Publication date: August 5, 2004
    Applicant: NPS Allelix Corporation
    Inventors: Methvin Isaac, Tao Xin, Tomislav Stefanac, Anne O'Brien, Kathleen Da Silva-Turcot, Jalaj Arora, Shawn Maddaford, Abdelmalik Slassi
  • Publication number: 20040152741
    Abstract: The present invention relates to compounds of Formula 1, 1
    Type: Application
    Filed: September 8, 2003
    Publication date: August 5, 2004
    Applicant: NPS Allelix Corporation
    Inventors: Methvin Isaac, Tao Xin, Louise Edwards, Leah Begleiter, Tomislav Stefanac, Anne O'Brien, Kathleen Da Silva-Turcot, Jalaj Arora, Shawn Maddaford, Abdelmalik Slassi
  • Publication number: 20030207809
    Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
    Type: Application
    Filed: April 21, 2003
    Publication date: November 6, 2003
    Applicant: NPS ALLELIX CORPORATION
    Inventor: Daniel J. Drucker
  • Publication number: 20030162703
    Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
    Type: Application
    Filed: November 14, 2002
    Publication date: August 28, 2003
    Applicant: NPS Allelix Corporation
    Inventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner Smith
  • Patent number: 6579987
    Abstract: Provided, among other things, is a compound of Formula I: wherein: Ar1 and Ar2 are independently selected aryl groups, optionally substituted with up to five substituents independently selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloalkyloxy, heterocycloalkyl, heterocycloalkyloxy, alkanoyl, thioalkyl, aralkyl, aralkyloxy, aryloxyalkyl, aryloxyalkoxy, cycloalkyl-substituted alkyl, cycloalkyloxy-substituted alkyl, cycloalkyl-substituted alkoxy, cycloalkyloxy-substituted alkoxy, heterocycloalkyl-substituted alkyl, heterocycloalkyloxy-substituted alkyl, heterocycloalkyl-substituted alkoxy, heterocycloalkyloxy-substituted alkoxy, thioaryl, aralkylthio, thioaryl-alkyl, aralkylthioalkyl, halo, NO2, CF3, CN, OH, alkylenedioxy, SO2NRR′, NRR′, CO2R (where R and R′ are independently selected from the group consisting of H and alkyl), and a second aryl group, which may be substituted as above; R1 is selected from the group consisting of H and alkyl; R2 is sele
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 17, 2003
    Assignee: NPS Allelix Corporation
    Inventors: Ian Egle, Jennifer Frey, Methvin Isaac
  • Publication number: 20030092769
    Abstract: Provided, among other things, is a compound of Formula I: 1
    Type: Application
    Filed: December 20, 2002
    Publication date: May 15, 2003
    Applicant: NPS Allelix Corporation
    Inventors: Ian Egle, Jennifer Frey, Methvin Isaac
  • Patent number: 6482609
    Abstract: A lysolipid receptor, a human EDG-4 receptor, a method of identifying lysolipid receptors involved in inflammatory response and the lysolipid receptors so identified, and a method of identifying ligands which interact with such lysolipid receptors.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: November 19, 2002
    Assignee: NPS Allelix Corporation
    Inventors: Donald G. Munroe, Rajender Kamboj, Diana Peters, Fatemch Kooshesh, Tejal B. Vyas, Ashwani K. Gupta
  • Patent number: 6406868
    Abstract: Described herein are isolated polynucleotides which code for an AMPA-type human CNS receptor, designated the human GluR1B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing the receptor is disclosed.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: June 18, 2002
    Assignee: NPS Allelix Corporation
    Inventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
  • Patent number: 6403323
    Abstract: Described herein are isolated polynucleotides which code for a family of AMPA-type human CNS receptors. The receptors are characterized structurally and the construction and use of cell lines expressing these receptors are disclosed.
    Type: Grant
    Filed: June 8, 1994
    Date of Patent: June 11, 2002
    Assignee: NPS Allelix Corporation
    Inventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
  • Patent number: 6391566
    Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. This neurotransmission has been found to be modulated by certain modulatory proteins. DNA coding for a family of such modulatory proteins has now been isolated and the modulatory proteins have been characterized. Herein described are recombinant cell lines which produce these modulatory proteins as heterologous membrane-bound products. Also described are related aspects of the invention, which are of commercial significance, including the use of cell lines which express the modulatory proteins either homomerically, or hotoromorically in a complex with an NMDA receptor, as a tool for discovery of compounds which affect the function of the modulatory proteins.
    Type: Grant
    Filed: June 23, 1994
    Date of Patent: May 21, 2002
    Assignee: NPS Allelix Corporation
    Inventors: Robert L. Foldes, Sally-Lin Adams, Rajender Kamboj
  • Patent number: 6333161
    Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors of the kainate-binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commercial significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.
    Type: Grant
    Filed: January 6, 1994
    Date of Patent: December 25, 2001
    Assignee: NPS Allelix Corporation
    Inventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt